Dr. David Saravitz

Dr. David Saravitz

Williams Mullen

Contact
View Bio
RSS

Latest Posts › Apotex

Share:

Biosimilar “Patent Dance” Does Not Permit Sidestepping of 180-Day Notice

On July 5, 2016, the U.S. Court of Appeals for the Federal Circuit (Federal Circuit) unanimously ruled in Amgen v. Apotex that biosimilar makers must provide brand-name rivals with a 180-day notice only after receipt of...more

7/15/2016  /  Amgen , Apotex , Biosimilars , BPCIA , Commercial Marketing , FDA Approval , Injunctive Relief , Notice Requirements , Patent Dance , Pharmaceutical Industry
1 Results
 / 
View per page
Page: of 1

"My best business intelligence, in one easy email…"

Your first step to building a free, personalized, morning email brief covering pertinent authors and topics on JD Supra:
Sign up Log in
*By using the service, you signify your acceptance of JD Supra's Privacy Policy.
- hide
- hide